IGC Pharma, Inc.
General ticker "IGC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $30.7M (TTM average)
IGC Pharma, Inc. does not follow the US Stock Market performance with the rate: -14.0%.
Estimated limits based on current volatility of 3.1%: low 0.26$, high 0.27$
Factors to consider:
- Total employees count: 70 (+4.5%) as of 2025
- US accounted for 87.7% of revenue in the fiscal year ended 2024-03-31
- Top business risk factors: Inability to achieve profitability, AI risks, Capital raising, Strategic risks and growth management, Geopolitical risks
- Price in estimated range
- Earnings for 15 months up through Q1 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-03-31 to 2027-03-31
- 2025-03-31 to 2026-03-31 estimated range: [0.21$, 0.55$]
- 2026-03-31 to 2027-03-31 estimated range: [0.22$, 0.56$]
Financial Metrics affecting the IGC estimates:
- Positive: with PPE of -3.4 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Inventory ratio change, % of -1.69 <= -0.75
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Shareholder equity ratio, % of 72.37 > 64.23
Short-term IGC quotes
Long-term IGC plot with estimates
Financial data
| YTD | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|
| Operating Revenue | $1.34MM | $1.27MM | $1.19MM |
| Operating Expenses | $11.14MM | $8.72MM | $11.39MM |
| Operating Income | $-9.80MM | $-7.45MM | $-10.20MM |
| Non-Operating Income | $-3.20MM | $0.33MM | $3.65MM |
| R&D Expense | $3.77MM | $3.65MM | $5.19MM |
| Income(Loss) | $-13.00MM | $-7.12MM | $-6.55MM |
| Net Income(Loss)* | $-13.00MM | $-7.12MM | $-6.55MM |
| Stockholders Equity | $7.32MM | $6.33MM | $6.12MM |
| Inventory | $1.54MM | $1.36MM | $0.64MM |
| Assets | $9.90MM | $8.75MM | $9.19MM |
| Operating Cash Flow | $-5.20MM | $-4.79MM | $-5.94MM |
| Capital expenditure | $0.52MM | $0.48MM | $0.16MM |
| Investing Cash Flow | $-0.32MM | $-0.44MM | $-0.19MM |
| Financing Cash Flow | $3.52MM | $4.45MM | $5.93MM |
| Earnings Per Share** | $-0.22 | $-0.09 | $-0.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.